Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

Two year survival rate of 50.8 percent for Vidaza versus 26.2 for

conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to

conventional care regimens Only agent to demonstrate survival benefit in MDS compared to conventional

care regimens

Only epigenetic modifier to show survival benefit in cancer

Stratified log-rank p-value = 0.0001, Hazard ratio = 0.58

Largest study ever conducted in higher-risk MDS

BOULDER, Colo., Aug. 2 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced topline results from the multi-institutional, international, randomized, Phase 3 controlled trial of Vidaza(R) (azacitidine for injection) versus conventional care regimens (CCR) in the treatment of patients with higher-risk myelodysplastic syndromes (MDS). In the primary endpoint analysis, Vidaza treatment was associated with a median survival of 24.4 months versus 15 months for those receiving CCR treatment, an improvement of 9.4 months with a stratified log-rank p-value of 0.0001. The hazard ratio describing this treatment effect was 0.58 (95 percent confidence interval of 0.43 to 0.77). Two-year survival rates were 50.8 percent versus 26.2 percent for patients receiving Vidaza versus CCR (p<0.0001). Median number of treatment cycles was nine for Vidaza.

The survival benefits of Vidaza were consistent regardless of the CCR treatment option (best supportive care (BSC) alone, low-dose cytarabine plus BSC or standard chemotherapy plus BSC) utilized in the control arm.

"These landmark results, showing a significant improvement in survival
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/10/2014)... , 11. Juli 2014 /PRNewswire/ ... Kameras für die molekulare Bildgebung, einschließlich ... heute die CE-Zulassung für sein Navigator ... kann Dilon das Produkt jetzt europaweit ... den Großteil der europäischen Länder ausgedehnt ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Sigma-Aldrich Corporation (NASDAQ: SIAL ) will ... KeyBanc Capital Markets 2011 Basic Materials ... InterContinental, Boston, MA, presenting at 9:00 AM (Eastern). ... at the Grand Hyatt, New York, NY, presenting at ...
... SimonMed and Cox Business have partnered to make a ... patients in the Valley and across the state at ... is the first dedicated outpatient offering of breast tomosynthesis ... in Scottsdale. Sub-specialty trained radiologists at SimonMed ...
Cached Medicine Technology:Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences 2SimonMed and Cox Business Bring Breast Tomosynthesis to Arizona 2
(Date:7/13/2014)... 2014 The North American water storage systems ... to $5,450 million by 2018, at a CAGR of 21.0%, ... expanding at a rapid pace in North America. The U.S. ... on water & wastewater storage and collection, and the increased ... is expanding at a healthy rate in Canada, and is ...
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
(Date:7/13/2014)... 13, 2014 Fuel additives are chemicals, ... diesel, jet fuel, kerosene, and so on, in order ... for reducing the corrosion effects caused by fuels and ... to any fuel, provide economies of scale in the ... the overall cost of the fuel products. , The ...
(Date:7/13/2014)... 13, 2014 MarketsandMarkets recently conducted ... Modeling; 3D Scanning; 3D rendering; Layout and Animation; ... (2013 - 2018)”, which analyzes and studies the ... America, Western Europe, Eastern Europe, Middle East and ... draws the competitive landscape of the 3D imaging ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... new type of sensor for people with diabetes is being ... instead of blood, researchers report. Scientists at Brown University ... using artificial saliva. It uses light, metal and a special ... "Everybody knows that diabetics have to prick their fingers to ...
Breaking Medicine News(10 mins):Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3
... and supports the first module, targeting ... ... Today at the,Healthcare Information and Management Systems Society (HIMSS) 2008 Annual,Conference ... Tool (PSST), a software-based solution designed to,help healthcare organizations identify potential ...
... cell differentiation into different kinds of tissues in embryos, plays ... life, said researchers from Baylor College of Medicine in Houston ... Nature Medicine. Their findings may provide a basis for understanding ... bone. , We knew that Notch is important in patterning ...
... ... Advances Made in Understanding Biology of Addiction ,and That is Finally ... ... Although the American Medical,Association recognized addiction as a disease back in 1956, ...
... the Lesbian, Gay, Bisexual and Transgender ... Movement By Early Microsoft Employee Pride Foundation ... Pride Foundation of Seattle is honored,to announce the establishment of ... Weiland,s gift of $65 million is the largest single bequest,ever ...
... to Forfeit Certain Shares; Oracle to Reschedule ... Special Meeting for March 5, 2008, GREENWICH, ... OHAQW and OHAQU) ("Oracle"),announced today that it has reached an agreement ... and,Plan of Merger, dated as of December 3, 2007 and previously ...
... finds tobacco users diagnosed almost 7 years earlier than ... and people with significant exposure to secondhand smoke should ... years earlier than the current recommended age of 50, ... of Rochester Medical Center in New York analyzed the ...
Cached Medicine News:Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 2Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 3Health News:Microsoft Introduces Patient Safety Screening Tool to Stop Spread of In-Hospital Infections 4Health News:Notch controls bone formation and strength 2Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 2Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 3Health News:NEWSWEEK Cover: The Hunt for an Addiction Vaccine 4Health News:Ric Weiland Leaves $65 Million to Support Gay Rights and HIV/AIDS Organizations 2Health News:Ric Weiland Leaves $65 Million to Support Gay Rights and HIV/AIDS Organizations 3Health News:Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15% 2Health News:Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15% 3Health News:Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15% 4Health News:Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Agree in Principle to Amend Merger Agreement to Reduce Consideration by 15% 5Health News:Earlier Colon Cancer Screens Urged for Smokers 2
VascoTwist is a low profile unipolar permanent pacing lead with a retractable screw. Due to advanced technology VascoTwist 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: